Rona Therapeutics, a Shangai, China-based fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, closed a $33m Series A financing.
Backers included Lilly Asia Ventures, CMB International, Platanus, Fontus Capital and Lanting Capital.
The company intends to use the funds to advance its proprietary delivery platform and initial pipeline of therapeutics.
Founded in 2021 and Stella SHI, CEO and co-founder, Rona Therapeutics aims to establish innovative RNA medicines with proprietary platform to enable therapeutics with more specific, stable and prolonged effects. Its RNA medicines are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems. The company is building facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to realize the potential of powerful RNA therapeutics.